Skip to main content
Journal cover image

Safety and Utility of Cardiopulmonary Exercise Testing in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia.

Publication ,  Journal Article
Scheel, PJ; Florido, R; Hsu, S; Murray, B; Tichnell, C; James, CA; Agafonova, J; Tandri, H; Judge, DP; Russell, SD; Tedford, RJ; Calkins, H ...
Published in: J Am Heart Assoc
February 4, 2020

Background Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is characterized by high arrhythmic burden and progressive heart failure, which can prompt referral for heart transplantation. Cardiopulmonary exercise testing (CPET) has an established role in risk stratification for advanced heart failure therapies, but has not been described in ARVC/D. This study sought to determine the safety and prognostic utility of CPET in patients with ARVC/D. Methods and Results Using the Johns Hopkins ARVC/D Registry, we examined patients with ARVC/D undergoing CPET. Baseline characteristics and transplant-free survival were compared on the basis of peak oxygen consumption (pVO2) (≤14 or >14 mL/kg per minute) and ventilatory efficiency (Ve/VCO2 slope ≤34 or >34). Thirty-eight patients underwent 50 CPETs. There were no sustained arrhythmic events. Twenty-nine patients achieved a maximal test. Patients with pVO2 ≤14 mL/kg per minute were more often men (P=0.042) compared with patients with pVO2 >14 mL/kg per minute. Patients with Ve/VCO2 slope >34 tended to have more moderate/severe right ventricular dilation (7/9 [78%] versus 10/26 [38%]; P=0.060) and clinical heart failure (8/9 [89%] versus 13/26 [50%]; P=0.056) compared with patients with Ve/VCO2 slope ≤34. Patients who underwent heart transplantation were more likely to have clinical heart failure (10/10 [100%] versus 13/28 [46%]; P=0.003). Patients with Ve/VCO2 slope >34 had worse transplant-free survival compared with patients with Ve/VCO2 slope ≤34 (n=35; hazard ratio, 6.57 [95% CI, 1.28-33.72]; log-rank P=0.010), whereas transplant-free survival was similar on the basis of pVO2 groups (n=29; hazard ratio, 3.38 [95% CI, 0.75-15.19]; log-rank P=0.092). Conclusions CPET is safe to perform in patients with ARVC/D. Ve/VCO2 slope may be used for risk stratification and guide referral for heart transplantation in ARVC/D.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Am Heart Assoc

DOI

EISSN

2047-9980

Publication Date

February 4, 2020

Volume

9

Issue

3

Start / End Page

e013695

Location

England

Related Subject Headings

  • Young Adult
  • Risk Factors
  • Risk Assessment
  • Retrospective Studies
  • Registries
  • Progression-Free Survival
  • Predictive Value of Tests
  • Oxygen Consumption
  • Middle Aged
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Scheel, P. J., Florido, R., Hsu, S., Murray, B., Tichnell, C., James, C. A., … Gilotra, N. A. (2020). Safety and Utility of Cardiopulmonary Exercise Testing in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. J Am Heart Assoc, 9(3), e013695. https://doi.org/10.1161/JAHA.119.013695
Scheel, Paul J., Roberta Florido, Steven Hsu, Brittney Murray, Crystal Tichnell, Cynthia A. James, Julia Agafonova, et al. “Safety and Utility of Cardiopulmonary Exercise Testing in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia.J Am Heart Assoc 9, no. 3 (February 4, 2020): e013695. https://doi.org/10.1161/JAHA.119.013695.
Scheel PJ, Florido R, Hsu S, Murray B, Tichnell C, James CA, et al. Safety and Utility of Cardiopulmonary Exercise Testing in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. J Am Heart Assoc. 2020 Feb 4;9(3):e013695.
Scheel, Paul J., et al. “Safety and Utility of Cardiopulmonary Exercise Testing in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia.J Am Heart Assoc, vol. 9, no. 3, Feb. 2020, p. e013695. Pubmed, doi:10.1161/JAHA.119.013695.
Scheel PJ, Florido R, Hsu S, Murray B, Tichnell C, James CA, Agafonova J, Tandri H, Judge DP, Russell SD, Tedford RJ, Calkins H, Gilotra NA. Safety and Utility of Cardiopulmonary Exercise Testing in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. J Am Heart Assoc. 2020 Feb 4;9(3):e013695.
Journal cover image

Published In

J Am Heart Assoc

DOI

EISSN

2047-9980

Publication Date

February 4, 2020

Volume

9

Issue

3

Start / End Page

e013695

Location

England

Related Subject Headings

  • Young Adult
  • Risk Factors
  • Risk Assessment
  • Retrospective Studies
  • Registries
  • Progression-Free Survival
  • Predictive Value of Tests
  • Oxygen Consumption
  • Middle Aged
  • Male